Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report

Jpn J Ophthalmol. 2016 May;60(3):212-8. doi: 10.1007/s10384-016-0439-z. Epub 2016 Mar 28.

Abstract

Purpose: Lymphoproliferative disorders (LPDs) can develop in patients treated with methotrexate (MTX) and usually respond well to MTX withdrawal. Mucosa-associated lymphoid tissue (MALT) lymphoma is a relatively rare type of MTX-LPD. The development of MTX-LPD in the orbit has not been previously described. We here report a case of orbital MALT lymphoma that disappeared after MTX withdrawal in a patient treated with MTX for rheumatoid arthritis.

Case: A 78-year-old woman who complained of swelling of the left upper eyelid had been treated with MTX for >8 years for rheumatoid arthritis. Slit-lamp examination revealed a temporal subconjunctival mass, salmon pink in color, in the left eye. Fundus photographs also suggested the presence of a temporal tumor in the left orbit. [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography revealed highly integrated lesions in the left inferotemporal orbit and a left external iliac lymph node, a left obturator lymph node, and an inguinal lymph node. Pathologic analysis of a tumor biopsy specimen showed small- and medium-sized lymphocytes positive for CD20, MIB-1, and bcl-2 and negative for CD10, CD3, bcl-1, IgG4, and EBV-ISH. On the basis of these findings, we diagnosed the tumor as MTX-induced MALT lymphoma. The subconjunctival and orbital masses disappeared gradually over 10 months after MTX withdrawal and did not recur within 2 years.

Conclusion: This case of orbital MTX-LPD suggests that the possibility of MTX-LPD should be considered even for ocular tumors in patients treated with MTX.

Keywords: Malignant lymphoma; Methotrexate-associated lymphoproliferative disorder (MTX-LPD); Mucosa-associated lymphoid tissue (MALT) lymphoma; Orbital lymphoma; Rheumatoid arthritis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Female
  • Humans
  • Lymphoproliferative Disorders / chemically induced*
  • Lymphoproliferative Disorders / diagnosis
  • Methotrexate / adverse effects*
  • Methotrexate / therapeutic use
  • Orbital Diseases / chemically induced*
  • Orbital Diseases / diagnosis
  • Positron-Emission Tomography
  • Tomography, X-Ray Computed

Substances

  • Antirheumatic Agents
  • Methotrexate